NCT04150744

RFA Plus Carrizumab vs Carrizumab Alone for HCC

Radiofrequency Ablation Plus Carrizumab vs Carrizumab Alone for Moderate or Advanced Hepatocellular Carcinoma: A Real World Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS.

Detailed description

The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS. 120 patients were enrolled into two groups respectively, the experimental group and reference group.

Conditions

• Tumor Immunity
• Immunosuppression
• Radiofrequency Ablation

Interventions

Type	Name	Description
COMBINATION_PRODUCT	radiofrequency ablation	take advantage of RFA to destroy hepatocellular carcinoma by high temperature

Timeline

• Start date: 2020-08-01
• Primary completion: 2025-12-30
• Completion: 2026-12-30
• First posted: 2019-11-05
• Last updated: 2020-07-08

Locations

1 site across 1 country: China